During the Blizzard of Boxing Day, the New York Times editorialized on the FDA's decision to remove Avastin's indication for breast cancer. The Gray Lady was mostly supportive and neglected to say that many breast cancer organizations (including the Susan B. Komen Foundation) strongly believe that the agency made the wrong decision.
Alas, the editorial buried the lead in the final paragraph:
Alas, the editorial buried the lead in the final paragraph:
"Genentech plans to request a hearing with the F.D.A. to argue the case for retaining Avastin’s status as an approved breast cancer treatment. It should focus on proposing ways to identify the subset of women who can really benefit from Avastin."
The full editorial can be found here.
Burying the lead is one thing. Prematurely burying patients is something altogether different.
